Q-omics provides the consensus-scored ADIRF profile across patient tissues and cancer cell-line models. ADIRF expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ADIRF is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, ADIRF protein abundance shows 27,373 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight PAAD, KICH, and LUAD as cancer lineages where ADIRF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADIRF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADIRF survival associations across molecular data types. ADIRF RNA expression shows survival associations in the most cancer types (9), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADIRF RNA expression–survival associations across cancer types. High ADIRF expression shows unfavorable associations in PAAD, MESO, THCA, ESCA and SKCM, but favorable associations in BLCA. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for ADIRF RNA expression.
This table summarizes ADIRF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ADIRF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADIRF shows lower tumor expression in KICH and BRCA. The KICH box plot shows higher ADIRF RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p = .007).
This table shows molecular features associated with ADIRF in patient tissues and cancer cell lines. In patient samples, ADIRF shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ADIRF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
